- Home
- CGEM vs CCII Comparison
CGEM vs CCII Comparison
Compare CGEM & CCII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEM
- CCII
- Stock Information
- Founded
- CGEM 2016
- CCII 2024
- Country
- CGEM United States
- CCII United States
- Employees
- CGEM N/A
- CCII N/A
- Industry
- CGEM Biotechnology: Pharmaceutical Preparations
- CCII
- Sector
- CGEM Health Care
- CCII
- Exchange
- CGEM Nasdaq
- CCII Nasdaq
- Market Cap
- CGEM 366.3M
- CCII 350.7M
- IPO Year
- CGEM 2021
- CCII 2025
- Fundamental
- Price
- CGEM $5.95
- CCII $10.18
- Analyst Decision
- CGEM Strong Buy
- CCII
- Analyst Count
- CGEM 7
- CCII 0
- Target Price
- CGEM $26.00
- CCII N/A
- AVG Volume (30 Days)
- CGEM 789.8K
- CCII 79.8K
- Earning Date
- CGEM 11-06-2025
- CCII 01-01-0001
- Dividend Yield
- CGEM N/A
- CCII N/A
- EPS Growth
- CGEM N/A
- CCII N/A
- EPS
- CGEM N/A
- CCII N/A
- Revenue
- CGEM N/A
- CCII N/A
- Revenue This Year
- CGEM N/A
- CCII N/A
- Revenue Next Year
- CGEM N/A
- CCII N/A
- P/E Ratio
- CGEM N/A
- CCII N/A
- Revenue Growth
- CGEM N/A
- CCII N/A
- 52 Week Low
- CGEM $5.68
- CCII $10.07
- 52 Week High
- CGEM $17.98
- CCII $10.22
- Technical
- Relative Strength Index (RSI)
- CGEM 39.45
- CCII N/A
- Support Level
- CGEM $5.68
- CCII N/A
- Resistance Level
- CGEM $6.13
- CCII N/A
- Average True Range (ATR)
- CGEM 0.29
- CCII 0.00
- MACD
- CGEM 0.03
- CCII 0.00
- Stochastic Oscillator
- CGEM 28.42
- CCII 0.00
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
About CCII Cohen Circle Acquisition Corp. II Class A Ordinary Shares
Cohen Circle Acquisition Corp II is a blank check company.